Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PCVX with free AI briefings, catalyst countdowns, and dilution alerts.

PCVX · Vaxcyte, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.3B Cash on Hand
29.8mo Cash Runway
Follow PCVX by email Get an email when PCVX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PCVX, unsubscribe in one click. Privacy

📣 What PCVX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Seasonal Influenza Vaccine (SIV) (Flublok) Pneumococcal Disease Phase 3 · NCT07365826 Active not recruiting
Pneumococcal 21-Valent Conjugate Vaccine Pneumococcal Disease Phase 3 · NCT07284654 Completed
Pneumococcal 20-Valent Conjugate Vaccine Pneumococcal Vaccines Phase 3 · NCT07425392 Active not recruiting
31-valent pneumococcal conjugate vaccine Pneumococcal Vaccines Phase 3 · NCT07425392 Active not recruiting
31 valent pneumococcal conjugate vaccine Pneumococcal Disease Phase 3 · NCT07284654 Completed
24-Valent Pneumococcal Conjugate Vaccine Pneumococcal Vaccines Phase 2 · NCT05297578 Completed
24 valent pneumococcal conjugate vaccine Pneumococcal Vaccines Phase 1/2 · NCT05266456 Completed
VAX-A1 High Group A Streptococcal Infection Phase 1 · NCT07616934 Recruiting
VAX-A1 Mid Group A Streptococcal Infection Phase 1 · NCT07616934 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PCVX holds $2.3B in cash and short-term investments (as of Sep 30, 2026) and burns about $228.3M/quarter from operations, an estimated runway of 29.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 22 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PCVX files for a raise →

👥 Who Owns PCVX

Insiders 0.7% Institutions (487 holders) 99.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 20,798,907 13.14% 2026-06-30
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 18,136,166 11.46% 2026-10-31
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 18,040,375 11.40% 2026-07-31
RA Capital Management, L.P. Institution (13G, 5%+) 12,974,599 8.20% 2026-03-31
Wellington Management Group LLP Institution (13G, 5%+) 7,733,961 4.89% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 7,252,053 4.58% 2026-03-31
Grant Pickering
CHIEF EXECUTIVE OFFICER, Director · +137,000 options
Insider 563,117 0.36% 2026-09-08
Andrew Guggenhime
PRESIDENT AND CFO · +216,827 options
Insider 157,166 0.10% 2026-09-08
Jim Wassil
EVP, Chief Scientific Ofc, COO · +44,148 options
Insider 145,435 0.09% 2026-11-02
Harpreet S. Dhaliwal
Chief Technical Ops Officer · +11,000 options
Insider 68,085 0.04% 2026-11-11
Luis Jodar
Chief Medical Officer · +88,254 options
Insider 52,632 0.03% 2026-09-04
Elvia Cowan
SVP, Finance & CAO · +71,068 options
Insider 27,860 0.02% 2026-11-02

Share count 158,299,981 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PCVX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PCVX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.